Adhesion molecules: Potential therapeutic and diagnostic implications

Methods in Molecular Biology

Volumn 663, Issue , 2010, Pages 261-276

  Mousa, Shaker A ^a  

^a Pharmaceutical Research Institute at Albany   (United States)

Author keywords

4 1; 4 7; 5 1; IIb 3; v 3; v 5; angiogenesis; apopotosis; CAM inhibitors; extracellular matrix proteins; ICAM; immunoglobulins; inflammatory and immune disorders; Integrins; osteoporosis; PECAM; restenosis; selectins; soluble adhesion molecules; thrombosis; VCAM

Indexed keywords

ANGINA;

ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; IMMUNOGLOBULIN; INTEGRIN; SELECTIN;

ADULT; ARTICLE; CELL LINE; CELL MOTION; CHEMISTRY; CYTOLOGY; DIAGNOSIS; DRUG ANTAGONISM; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NEUTROPHIL; SOLUBILITY; THERAPY;

ADULT; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; CELL LINE; CELL MOVEMENT; DIAGNOSIS; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNOGLOBULINS; INTEGRINS; MALE; MIDDLE AGED; NEUTROPHILS; PLATELET AGGREGATION INHIBITORS; SELECTINS; SOLUBILITY; THERAPEUTICS;

EID: 77957672494     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60761-803-4_11     Document Type: Article

References (53)

1. Cox, D., Aoki, T., Seki, J., Motoyama, Y., and Yoshida, K. (1994) The pharmacology of the integrins Med Res Rev 14, 195-228.
2. Lal, H., Verma, S.K., Foster, D.M., Golden, H.B., Reneau, J.C., Watson, L.E., Singh, H., and Dostal, D.E. (2009) Integrins and proximal signaling mechanisms in cardiovascular disease Front Biosci 14, 2307-34.
3. Gold, H.K., Gimple, L.W., Yasuda, T., Leinbach, R.C., Werner, W., Holt, R., Jordan, R., Berger, H., Collen, D., and Coller, B.S. (1990) Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris J Clin Invest 86, 651-9.
4. Mousa, S., and Topol, E. Novel antiplatelet therapies: Recent advances in the development of platelet GPIIb/IIIa receptor antagonists. In: Serruys, P.W., and Holmes, D., eds. Current Review of Interventional Cardiology, 3rd edition. Philadelphia, PA: Current Medicine;1997:114-29.
5. Mousa, S.A., Bozarth, J.M., Forsythe, M.S., Jackson, S.M., Leamy, A., Diemer, M.M., Kapil, R.P., Knabb, R.M., Mayo, M.C., Pierce, S.K., et al. (1994) Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist Circulation 89, 3-12.
6. Mousa, S.A., Bozarth, J.M., Forsythe, M.S., Lorelli, W., Thoolen, M.J., Ramachandran, N., Jackson, S., De Grado, W., and Reilly, T.M. (1993) Antiplatelet efficacy and specificity of DMP728, a novel platelet GPIIb/IIIa receptor antagonist Cardiology 83, 374-82.
7. van't Hof, A.W., and Valgimigli, M. (2009) Defining the role of platelet glycoprotein receptor inhibitors in STEMI: Focus on tirofiban Drugs 69, 85-100.
8. Brooks, P.C., Clark, R.A., and Cheresh, D.A. (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis Science 264, 569-71.
9. Brooks, P.C.,Montgomery, A.M., Rosenfeld, M., Reisfeld, R.A., Hu, T., Klier, G., and Cheresh, D.A. (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels Cell 79, 1157-64.
10. Brandley, B.K., Swiedler, S.J., and Robbins, P.W. (1990) Carbohydrate ligands of the LEC cell adhesion molecules Cell 63, 861-3.
11. Lasky, L.A., Singer, M.S., Dowbenko, D., Imai, Y., Henzel, W.J., Grimley, C., Fennie, C., Gillett, N.,Watson, S.R., and Rosen, S.D. (1992) An endothelial ligand for L-selectin is a novel mucin-like molecule Cell 69, 927-38.
12. Lasky, L.A. (1992) Selectins: Interpreters of cell-specific carbohydrate information during inflammation Science 258, 964-9.
13. Phillips, M.L., Nudelman, E., Gaeta, F.C., Perez, M., Singhal, A.K., Hakomori, S., and Paulson, J.C. (1990) ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex Science 250, 1130-2.
14. Mulligan, M.S., Paulson, J.C., De Frees, S., Zheng, Z.L., Lowe, J.B., and Ward, P.A. (1993) Protective effects of oligosaccharides in P-selectin-dependent lung injury Nature 364, 149-51.
15. Weyrich, A.S., Ma, X.Y., Lefer, D.J., Albertine, K.H., and Lefer, A.M. (1993) In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury J Clin Invest 91, 2620-9.
16. Hullinger, T., DeGraaf, G., Hartman, J., and Shebuski, R. (1995) The effect of P-selectin blockade on neointimal lesion development in a primate carotid injury model FASEB 9.
17. Taylor, M.E., and Drickamer, K. (2007) Paradigms for glycan-binding receptors in cell adhesion Curr Opin Cell Biol 19, 572-7.
18. Topol, E.J., Califf, R.M., Weisman, H.F., Ellis, S.G., Tcheng, J.E., Worley, S., Ivanhoe, R., George, B.S., Fintel, D., Weston, M., et al. (1994) Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. The EPIC investigators Lancet 343, 881-6.
19. Berlin, C., Berg, E.L., Briskin, M.J., Andrew, D.P., Kilshaw, P.J., Holzmann, B., Weissman, I.L., Hamann, A., and Butcher, E.C. (1993) Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1 Cell 74, 185-95.
20. Elices, M.J., Osborn, L., Takada, Y., Crouse, C., Luhowskyj, S., Hemler, M.E., and Lobb, R.R. (1990) VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site Cell 60, 577-84.
21. Issekutz, T.B. (1991) Inhibition of in vivo lymphocyte migration to inflammation and homing to lymphoid tissues by the TA-2 monoclonal antibody. A likely role for VLA-4 in vivo J Immunol 147, 4178-84.
22. Hamann, A., Andrew, D.P., Jablonski- Westrich, D., Holzmann, B., and Butcher, E.C. (1994) Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in vivo J Immunol 152, 3282-93.
23. Springer, T.A. (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm Cell 76, 301-14.
24. Yednock, T.A., Cannon, C., Fritz, L.C., Sanchez-Madrid, F., Steinman, L., and Karin, N. (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin Nature 356, 63-6.
25. Cannella, B., and Raine, C.S. (1995) The adhesion molecule and cytokine profile of multiple sclerosis lesions Ann Neurol 37, 424-35.
26. Cerf-Bensussan, N., Jarry, A., Brousse, N., Lisowska-Grospierre, B., Guy-Grand, D., and Griscelli, C. (1987) A monoclonal antibody (HML-1) defining a novel membrane molecule present on human intestinal lymphocytes Eur J Immunol 17, 1279-85.
27. Kim, S., Bell, K., Mousa, S.A., and Varner, J.A. (2000) Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin Am J Pathol 156, 1345-62.
28. Cue, D., Southern, S.O., Southern, P.J., Prabhakar, J., Lorelli, W., Smallheer, J.M., Mousa, S.A., and Cleary, P.P. (2000) A nonpeptide integrin antagonist can inhibit epithelial cell ingestion of Streptococcus pyogenes by blocking formation of integrin alpha 5beta 1-fibronectin-M1 protein complexes Proc Natl Acad Sci USA 97, 2858-63.
29. The EPIC Investigators (1994) Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty N Engl J Med 330, 956-61.
30. Kleiman, N.S., Ohman, E.M., Califf, R.M., George, B.S., Kereiakes, D., Aguirre, F.V., Weisman, H., Schaible, T., and Topol, E.J. (1993) Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study J Am Coll Cardiol 22, 381-9.
31. Tcheng, J.E., Ellis, S.G., George, B.S., Kereiakes, D.J., Kleiman, N.S., Talley, J.D., Wang, A.L., Weisman, H.F., Califf, R.M., and Topol, E.J. (1994) Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in highrisk coronary angioplasty Circulation 90, 1757-64.
32. Tcheng, J.E., Harrington, R.A., Kottke- Marchant, K., Kleiman, N.S., Ellis, S.G., Kereiakes, D.J., Mick, M.J., Navetta, F.I., Smith, J.E., Worley, S.J., et al. (1995) Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT investigators Circulation 91, 2151-7.
33. Peerlinck, K., De Lepeleire, I., Goldberg,M., Farrell, D., Barrett, J., Hand, E., Panebianco, D., Deckmyn, H., Vermylen, J., and Arnout, J. (1993) MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man Circulation 88, 1512-7.
34. Cannon, C.P., McCabe, C.H., Borzak, S., Henry, T.D., Tischler, M.D., Mueller, H.S., Feldman, R., Palmeri, S.T., Ault, K., Hamilton, S.A., Rothman, J.M., Novotny, W.F., and Braunwald, E. (1998) Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI 12 trial. Thrombolysis in myocardial infarction Circulation 97, 340-9.
35. Muller, T.H., Weisenberger, H., Brickl, R., Narjes, H., Himmelsbach, F., and Krause, J. (1997) Profound and sustained inhibition of platelet aggregation by fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, lefradafiban, in men Circulation 96, 1130-8.
36. Simpfendorfer, C., Kottke-Marchant, K., Lowrie, M., Anders, R.J., Burns, D.M., Miller, D.P., Cove, C.S., DeFranco, A.C., Ellis, S.G., Moliterno, D.J., Raymond, R.E., Sutton, J.M., and Topol, E.J. (1997) First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebocontrolled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions Circulation 96, 76-81.
37. Harrington, R.A., Armstrong, P.W., Graffagnino, C., Van De Werf, F., Kereiakes, D.J., Sigmon, K.N., Card, T., Joseph, D.M., Samuels, R., Granett, J., Chan, R., Califf, R.M., and Topol, E.J. (2000) Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease Circulation 102, 728-35.
38. Mousa, S., and Wityak, J. (1998) Orally active Isoxazoline GOIIb/IIIa antagonists Cardiovas Drug Rev 16, 48-61.
39. Quinn, M., and Fitzgerald, D.J. (1998) Long-term administration of glycoprotein IIb/IIIa antagonists Am Heart J 135, S113-8.
40. Vorchheimer, D.A., and Fuster, V. (1998) Oral platelet glycoprotein IIb/IIIa receptor antagonists: The present challenge is safety Circulation 97, 312-4.
41. Mousa, S.A., Bozarth, J.M., Edwards, S., Carroll, T., and Barrett, J. (1998) Novel technetium-99m-labeled platelet GPIIb/IIIa receptor antagonists as potential imaging agents for venous and arterial thrombosis Coron Artery Dis 9, 131-41.
42. Srivatsa, S.S., Fitzpatrick, L.A., Tsao, P.W., Reilly, T.M., Holmes, D.R., Jr., Schwartz, R.S., and Mousa, S.A. (1997) Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: Evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formation Cardiovasc Res 36, 408-28.
43. Liaw, L., Skinner, M.P., Raines, E.W., Ross, R., Cheresh, D.A., Schwartz, S.M., and Giachelli, C.M. (1995) The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro J Clin Invest 95, 713-24.
44. Yue, T.L., McKenna, P.J., Ohlstein, E.H., Farach-Carson, M.C., Butler, W.T., Johanson, K., McDevitt, P., Feuerstein, G.Z., and Stadel, J.M. (1994) Osteopontin-stimulated vascular smooth muscle cell migration is mediated by beta 3 integrin Exp Cell Res 214, 459-64.
45. van der Zee, R., Murohara, T., Passeri, J., Kearney, M., Cheresh, D.A., and Isner, J.M. (1998) Reduced intimal thickening following alpha(v)beta3 blockade is associated with smooth muscle cell apoptosis Cell Adhes Commun 6, 371-9.
46. Kerr, J.S., Slee, A.M., and Mousa, S.A. (2002) The alpha v integrin antagonists as novel anticancer agents: An update Expert Opin Investig Drugs 11, 1765-74.
47. Oba, M., Fukushima, S., Kanayama, N., Aoyagi, K., Nishiyama, N., Koyama, H., and Kataoka, K. (2007) Cyclic RGD peptideconjugated polyplex micelles as a targetable gene delivery system directed to cells possessing alphavbeta3 and alphavbeta5 integrins Bioconjug Chem 18, 1415-23.
48. Flavin, T., Ivens, K., Rothlein, R., Faanes, R., Clayberger, C., Billingham, M., and Starnes, V.A. (1991) Monoclonal antibodies against intercellular adhesion molecule 1 prolong cardiac allograft survival in cynomolgus monkeys Transplant Proc 23, 533-4.
49. Haug, C.E., Colvin, R.B., Delmonico, F.L., Auchincloss, H., Jr., Tolkoff-Rubin, N., Preffer, F.I., Rothlein, R., Norris, S., Scharschmidt, L., and Cosimi, A.B. (1993) A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients Transplantation 55, 766-72; Discussion 72-3.
50. Rosenblum, W.I., Nelson, G.H., Wormley, B., Werner, P., Wang, J., and Shih, C.C. (1996) Role of platelet-endothelial cell adhesion molecule (PECAM) in platelet adhesion/aggregation over injured but not denuded endothelium in vivo and ex vivo Stroke 27, 709-11.
51. Muller, W.A., and Randolph, G.J. (1999) Migration of leukocytes across endothelium and beyond: Molecules involved in the transmigration and fate of monocytes J Leukoc Biol 66, 698-704.
52. Gearing, A.J., and Newman, W. (1993) Circulating adhesion molecules in disease Immunol Today 14, 506-12.
53. Newman, W., Beall, L.D., Carson, C.W., Hunder, G.G., Graben, N., Randhawa, Z.I., Gopal, T.V., Wiener-Kronish, J., and Matthay, M.A. (1993) Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock J Immunol 150, 644-54.